
Sign up to save your podcasts
Or


Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937
By BMJ Group4.2
99 ratings
Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937

502 Listeners

40 Listeners

46 Listeners

304 Listeners

5 Listeners

7 Listeners

5 Listeners

3 Listeners

1 Listeners

3 Listeners

25 Listeners

40 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

16 Listeners

3 Listeners

29 Listeners

23 Listeners

136 Listeners

1,061 Listeners

81 Listeners

0 Listeners